Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 492-500 , October 2010

Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

  • John Araujo

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Genitourinary Center, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. Tel.: +1 713 792 2830; fax: +1 713 792 1654.
    • ,
  • Christopher Logothetis

      Affiliations

    • Tel.: +1 713 563 7210; fax: +1 713 792 1654.

Received 22 December 2009 ,Revised 2 February 2010 ,Accepted 6 February 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0305-7372(10)00035-6

doi: 10.1016/j.ctrv.2010.02.015

Cancer Treatment Reviews
Volume 36, Issue 6 , Pages 492-500 , October 2010

Article Tools

* Image Usage & Resolution